Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 | Zendy

Robert K. Flamm | Zendy; Rodrigo E. Mendes | Zendy; James E. Ross | Zendy; Hélio S. Sader | Zendy; Ronald N. Jones | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Author(s) -

Robert K. Flamm,

Rodrigo E. Mendes,

James E. Ross,

Hélio S. Sader,

Ronald N. Jones

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02112-12

Subject(s) - linezolid , staphylococcus aureus , streptococcus pneumoniae , microbiology and biotechnology , viridans streptococci , medicine , streptococcus , antibiotics , bacteria , biology , vancomycin , genetics

The LEADER surveillance program monitors the in vitro activity of linezolid and comparator agents against Gram-positive bacteria in the United States. In its eighth consecutive year (2011), a total of 60 medical centers from the United States, including seven medical centers specializing in children's health care contributed a total of 7,303 Gram-positive pathogens. The MIC(90) value for Staphylococcus aureus was 2 μg/ml, and for coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, β-hemolytic streptococci, and viridans group streptococci, the MIC(90) was 1 μg/ml. The "all organism" linezolid-resistant and nonsusceptible rate was only 0.19%.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research